Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GTHP Guided Therapeutics	$0.28 +8.4%	$0.24	$0.06 ▼ $0.32	$20.38M	0.18	10,371 shs	4,739 shs
MYO Myomo	$0.98 -0.5%	$2.12	$0.92 ▼ $7.17	$37.04M	1.4	1.11 million shs	3.25 million shs
TELA TELA Bio	$1.58 -1.3%	$1.86	$0.86 ▼ $3.26	$63.39M	0.93	82,650 shs	69,044 shs
ZYXI Zynex	$1.52 -4.4%	$2.20	$1.23 ▼ $9.42	$48.17M	0.91	535,798 shs	73,221 shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GTHP Guided Therapeutics	+8.35%	+94.90%	+10.00%	+120.00%	+133.25%
MYO Myomo	-0.51%	-46.72%	-50.00%	-72.69%	-81.36%
TELA TELA Bio	-1.25%	-8.14%	-20.60%	+43.64%	-47.85%
ZYXI Zynex	-4.40%	+4.83%	-33.04%	-38.71%	-78.86%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GTHP Guided Therapeutics	0.5183 of 5 stars	0.0	3.0	2.0	1.7	0.0
MYO Myomo	3.2487 of 5 stars	3.5	5.0	1.5	2.5	0.6
TELA TELA Bio	2.7347 of 5 stars	3.3	4.0	2.2	1.7	0.6
ZYXI Zynex	2.6474 of 5 stars	3.2	1.0	2.6	1.7	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GTHP Guided Therapeutics	0.00	N/A	N/A	N/A
MYO Myomo	3.00	Buy	$8.17	737.61% Upside
TELA TELA Bio	2.50	Moderate Buy	$4.50	184.81% Upside
ZYXI Zynex	2.33	Hold	$4.90	222.37% Upside

Current Analyst Ratings Breakdown

Latest GTHP, MYO, ZYXI, and TELA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2025	MYO Myomo	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$9.50 ➝ $5.00
8/1/2025	ZYXI Zynex	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$3.70
8/1/2025	ZYXI Zynex	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
7/15/2025	ZYXI Zynex	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Perform ➝ Sector Perform	$4.00 ➝ $3.00
6/30/2025	ZYXI Zynex	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00
6/26/2025	MYO Myomo	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
6/23/2025	MYO Myomo	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$10.00 ➝ $8.00
6/5/2025	MYO Myomo	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$11.00 ➝ $11.50

(Data available from 8/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GTHP Guided Therapeutics	$10K	2,207.70	N/A	N/A	($0.12) per share	-2.29
MYO Myomo	$32.55M	1.13	N/A	N/A	$0.47 per share	2.07
TELA TELA Bio	$69.30M	0.90	N/A	N/A	$0.23 per share	6.87
ZYXI Zynex	$192.35M	0.24	$0.23 per share	6.51	$0.04 per share	38.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GTHP Guided Therapeutics	-$2.42M	-$0.05	N/A	∞	N/A	N/A	N/A	-208.01%	N/A
MYO Myomo	-$6.18M	-$0.23	N/A	N/A	N/A	-22.87%	-50.87%	-27.00%	N/A
TELA TELA Bio	-$37.84M	-$1.12	N/A	N/A	N/A	-54.12%	-329.48%	-57.34%	N/A
ZYXI Zynex	$2.99M	-$0.94	N/A	3.23	N/A	-19.79%	-78.54%	-16.70%	10/30/2025 (Estimated)

Latest GTHP, MYO, ZYXI, and TELA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/14/2025	Q2 2025	GTHP Guided Therapeutics	N/A	-$0.01	N/A	-$0.01	N/A	$0.12 million
8/11/2025	Q2 2025	TELA TELA Bio	-$0.18	-$0.22	-$0.04	-$0.22	$20.67 million	$20.20 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GTHP Guided Therapeutics	N/A	N/A	N/A	N/A	N/A
MYO Myomo	N/A	N/A	N/A	N/A	N/A
TELA TELA Bio	N/A	N/A	N/A	N/A	N/A
ZYXI Zynex	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GTHP Guided Therapeutics	N/A	0.14	0.03
MYO Myomo	0.08	2.39	2.37
TELA TELA Bio	4.14	3.19	3.40
ZYXI Zynex	0.56	0.62	0.45

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GTHP Guided Therapeutics	9.69%
MYO Myomo	44.99%
TELA TELA Bio	94.35%
ZYXI Zynex	29.68%

Insider Ownership

Company	Insider Ownership
GTHP Guided Therapeutics	66.83%
MYO Myomo	4.79%
TELA TELA Bio	4.70%
ZYXI Zynex	49.28%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GTHP Guided Therapeutics	5	80.28 million	26.63 million	Not Optionable
MYO Myomo	90	37.80 million	35.99 million	Not Optionable
TELA TELA Bio	120	39.62 million	37.75 million	Optionable
ZYXI Zynex	770	30.30 million	15.37 million	Optionable

GTHP, MYO, ZYXI, and TELA Headlines

Recent News About These Companies

Zynex, Inc. Investors: Company Investigated by the Portnoy Law Firm

August 14 at 4:21 PM | globenewswire.com

ZYNEX ALERT: Bragar Eagel & Squire, P.C. is Investigating Zynex, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

August 13 at 8:20 PM | globenewswire.com

Zynex Q2 Revenue Drops 55%

August 5, 2025 | fool.com

Zynex Inc. Faces Challenges Amid Strategic Shifts

August 4, 2025 | theglobeandmail.com

Zynex (NASDAQ:ZYXI) Raised to "Buy" at LADENBURG THALM/SH SH

August 2, 2025 | marketbeat.com

Zynex (NASDAQ:ZYXI) Rating Lowered to "Neutral" at HC Wainwright

August 2, 2025 | marketbeat.com

Zynex, Inc. (NASDAQ:ZYXI) Q2 2025 Earnings Call Transcript

August 1, 2025 | msn.com

HC Wainwright & Co. Downgrades Zynex (ZYXI)

August 1, 2025 | msn.com

Zynex, Inc.: Zynex Reports Second Quarter 2025 Financial Results

August 1, 2025 | finanznachrichten.de

Zynex Inc (ZYXI) Q2 2025 Earnings Report Preview: What to Look For

August 1, 2025 | finance.yahoo.com

Zynex, Inc. (ZYXI) Q2 2025 Earnings Call Transcript

July 31, 2025 | seekingalpha.com

Zynex Inc. (ZYXI) Reports Q2 Loss, Misses Revenue Estimates

July 31, 2025 | zacks.com

Zynex eyes growth revival under new CEO, advances oximeter technology

July 31, 2025 | proactiveinvestors.com

Zynex Reports Second Quarter 2025 Financial Results

July 31, 2025 | prnewswire.com

Zynex Sets Second Quarter 2025 Earnings Call

July 22, 2025 | prnewswire.com

Zynex (ZYXI) to Release Quarterly Earnings on Wednesday

July 16, 2025 | marketbeat.com

Zynex: New CEO Steven Dyson shares his vision â€“ ICYMI

July 12, 2025 | proactiveinvestors.com

Zynex: New CEO Steven Dyson shares his vision – ICYMI

July 12, 2025 | proactiveinvestors.com

Zynex Shareholder Sues Board, Execs Over Insurer’s Payment Pause

July 11, 2025 | news.bloomberglaw.comN

ZYNEX ALERT: Bragar Eagel & Squire, P.C. is Investigating Zynex, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

July 10, 2025 | globenewswire.com

Zynex CEO Thomas Sandgaard discusses leadership transition - ICYMI

July 5, 2025 | proactiveinvestors.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GTHP, MYO, ZYXI, and TELA Company Descriptions

Guided Therapeutics OTCMKTS:GTHP

$0.28 +0.02 (+8.35%)

As of 08/15/2025 02:51 PM Eastern

Guided Therapeutics, Inc., a medical technology company, focuses on developing medical devices. It focuses on the commercialization of LuViva, a non-invasive cervical cancer detection device that identifies cervical cancers and precancers painlessly, non-invasively, and at the point-of-care by scanning the cervix with light, then analyzing the light reflected and fluorescent light. The company was formerly known as SpectRx, Inc. and changed its name to Guided Therapeutics, Inc. in February 2008. Guided Therapeutics, Inc. was incorporated in 1992 and is based in Norcross, Georgia.

Myomo NYSEAMERICAN:MYO

$0.98 -0.01 (-0.51%)

Closing price 08/15/2025 04:10 PM Eastern

Extended Trading

$0.98 +0.01 (+0.72%)

As of 08/15/2025 08:00 PM Eastern

Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, China, Germany, and internationally. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living. It also provides the MyoPro 2, including control technology, configuration software and user interface, and pop-out battery for extended use of the brace; and MyoPro2+ that comprises 3D printed orthotics capability, software enhancements, and a design for donning and doffing of the device. Its products are designed to help improve function in adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury, and other neurological disorders. The company sells its products through various sales channels, including orthotics and prosthetics providers, the Veterans Administration, and its distributors. Myomo, Inc. was incorporated in 2004 and is headquartered in Boston, Massachusetts.

TELA Bio NASDAQ:TELA

$1.58 -0.02 (-1.25%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$1.56 -0.02 (-1.27%)

As of 08/15/2025 04:04 PM Eastern

TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.

Zynex NASDAQ:ZYXI

$1.52 -0.07 (-4.40%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$1.52 0.00 (0.00%)

As of 08/15/2025 07:55 PM Eastern

Zynex, Inc., together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body, and batteries for use in electrotherapy products. In addition, the company distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces for lumbar support, and braces for rehabilitation support. Further, it offers Zynex Fluid Monitoring System (CM-1500); Zynex Wireless Fluid Monitoring System (CM-1600), a noninvasive monitoring device designed to measure relative changes in fluid volume in adult patients; NiCO CO-Oximeter, a laser-based noninvasive co-oximeter; and HemeOx tHb Oximeter, a laser-based total hemoglobin pulse oximeter. The company provides its products for use in pain management and control; stroke and spinal cord injury rehabilitation; hemodynamic monitoring and intravascular volume monitoring; and pulse oximetry monitoring. It sells its products through direct sales force primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time